en
Scientific article
Case report
English

Successful treatment of neonatal rhesus hemolytic anemia with high doses of recombinant human erythropoietin

Published inPediatric hematology and oncology, vol. 18, no. 4, p. 279-282
Publication date2001
Abstract

The authors report the use of high-dose recombinant erythropoietin (r-HuEPO) in a full-term newborn baby with severe postnatal rhesus hemolytic anemia (RHA). Hemoglobin (Hb) value and reticulocyte count at day 13 of life were 59 g/L and 234 x 10(9)/L, respectively. Three days after the r-HuEPO (870 U/kg/d) administration, reticulocyte count had increased more than 4-fold and Hb rose to 73 g/L. r-HuEPO was gradually decreased after 18 days of treatment. No major side effect was observed. In selected cases of severe anemia due to hemolytic disorders, transfusions may be avoided by the use of high doses of r-HuEPO.

Keywords
  • Anemia, Hemolytic, Congenital/drug therapy/etiology
  • Erythropoietin/administration & dosage
  • Female
  • Hemoglobins/metabolism
  • Humans
  • Infant, Newborn
  • Recombinant Proteins
  • Reticulocyte Count
  • Rh Isoimmunization/blood/complications
  • Time Factors
  • Treatment Outcome
Citation (ISO format)
WACKER, Pierre et al. Successful treatment of neonatal rhesus hemolytic anemia with high doses of recombinant human erythropoietin. In: Pediatric hematology and oncology, 2001, vol. 18, n° 4, p. 279–282. doi: 10.1080/088800101750238595
Main files (1)
Article (Published version)
accessLevelRestricted
Identifiers
ISSN of the journal0888-0018
471views
0downloads

Technical informations

Creation05/11/2015 2:49:00 PM
First validation05/11/2015 2:49:00 PM
Update time03/14/2023 11:16:30 PM
Status update03/14/2023 11:16:29 PM
Last indexation01/16/2024 5:58:39 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack